GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Debt-to-EBITDA
中文

Bio-Techne (Bio-Techne) Debt-to-EBITDA : 2.12 (As of Dec. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Bio-Techne Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bio-Techne's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13 Mil. Bio-Techne's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $543 Mil. Bio-Techne's annualized EBITDA for the quarter that ended in Dec. 2023 was $262 Mil. Bio-Techne's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.12.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bio-Techne's Debt-to-EBITDA or its related term are showing as below:

TECH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.07   Med: 1.07   Max: 2.38
Current: 1.48

During the past 13 years, the highest Debt-to-EBITDA Ratio of Bio-Techne was 2.38. The lowest was 0.07. And the median was 1.07.

TECH's Debt-to-EBITDA is ranked worse than
51.25% of 279 companies
in the Biotechnology industry
Industry Median: 1.39 vs TECH: 1.48

Bio-Techne Debt-to-EBITDA Historical Data

The historical data trend for Bio-Techne's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Debt-to-EBITDA Chart

Bio-Techne Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.38 1.15 1.68 0.79 1.00

Bio-Techne Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 1.09 0.96 1.66 2.12

Competitive Comparison of Bio-Techne's Debt-to-EBITDA

For the Biotechnology subindustry, Bio-Techne's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Debt-to-EBITDA falls into.



Bio-Techne Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bio-Techne's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(11.199 + 443.766) / 457.112
=1.00

Bio-Techne's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(12.672 + 543.027) / 262.076
=2.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Bio-Techne  (NAS:TECH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Bio-Techne Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne (Bio-Techne) Business Description

Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Executives
Roeland Nusse director 473 TENNESSEE, PALO ALTO CA 94306
William Geist officer: PRESIDENT, PROTEIN SCIENCES 900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth director, officer: Chief Executive Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Robert V Baumgartner director 5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
Kim Kelderman officer: Pres. Diagnostics & Genom 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor officer: SVP Biotech 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel officer: Chief Financial Officer 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan director C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Alpna Seth director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Julie L Bushman director 185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Randolph C Steer director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413

Bio-Techne (Bio-Techne) Headlines